Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

PD-1 inhibitor plus VEGFR-2 inhibitor and chemotherapy versus chemotherapy alone for locally advanced gastric cancer: A systematic review and meta-analysis.

Muhammad Ansab, Shree Rath, Basanta Pathak et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16125

e16125 Background: Despite multimodality treatment, pathological response rates remain suboptimal in patients with locally...

Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial.

Hong Wu, Lianxin Liu, Sulai Liu et al. Jun 01, 2026 pp. 4014-4014 10.1200/jco.2026.44.16_suppl.4014

4014 Background: Checkpoint inhibitors combined with anti-angiogenic therapy represents one of the standard first-line the...

Impact of pre-treatment antibiotic exposure on immunotherapy outcomes in gastrointestinal malignancies: A multicenter propensity-matched real-world cohort study.

Swapna Gangasani, Madho Mal, Nayanika Chowdary Tummala et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15598

e15598 Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of gastrointestinal (GI) m...

Randomized phase 2 study to evaluate the efficacy and safety of silevertinib in combination with temozolomide in newly diagnosed patients with EGFRvIII-positive IDHwt MGMT unmethylated glioblastoma.

Patrick Y. Wen, Fabio M. Iwamoto, Rupesh Kotecha et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2098

TPS2098 Background: Targeted therapy for patients with newly diagnosed glioblastoma (ND-GBM) has made little progress. Fir...

Mortality trend from multiple myeloma with hypertensive diseases as a contributing cause in the United States, 1999–2024: A CDC WONDER analysis across age, sex, and geographic variables.

Siddhanta K.C., Maheen Rizwan, Mariam Mustafa et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19530

e19530 Background: Multiple myeloma (MM) is a malignancy frequently accompanied by comorbid conditions such as hypertensiv...

Efficacy and safety of camrelizumab combined with docetaxel and carboplatin as neoadjuvant therapy for triple-negative breast cancer: The HELEN-Trio 011 randomized clinical trial.

Zhenzhen Liu, Dechuang Jiao, Xianfu Sun et al. Jun 01, 2026 pp. 1009-1009 10.1200/jco.2026.44.16_suppl.1009

1009 Background: The KEYNOTE-522 trial demonstrated that adding a PD-1 inhibitor to neoadjuvant chemotherapy significantly...

Current real-world treatments in patients with metastatic colorectal cancer (mCRC) in US clinical practice.

Xiaoyun Pan, Orsolya Lunacsek, Jamie Grossman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15604

e15604 Background: As the landscape of mCRC treatment continues to evolve, it is important to understand real-world treatm...

Puxitatug samrotecan (AZD8205) vs chemotherapy in patients with B7-H4–selected advanced/metastatic endometrial cancer: The phase 3 randomized Bluestar-Endometrial01 (BE01)/GOG-3110/ENGOT-EN28 trial.

Stephanie Gaillard, Evelyn Cantillo, David Cibula et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5647

TPS5647 Background: The transmembrane glycoprotein B7-H4 is highly expressed in endometrial cancer (EC), with limited expr...

A phase II trial of binimetinib in combination with encorafenib in patients with pancreatic malignancies and a somatic <i>BRAF</i> <sup>V600E</sup> mutation.

Tara Tamar Arouchian, Tanios S. Bekaii-Saab, Brian M. Wolpin et al. Jun 01, 2026 pp. 4219-4219 10.1200/jco.2026.44.16_suppl.4219

4219 Background: Pancreatic ductal adenocarcinoma (PDAC) remains a notoriously difficult-to-treat malignancy, with limited...

Improving patient self-management in hepatocellular carcinoma using care sequence plans: A comparative survey study.

Maen Abdelrahim, Abdullah Esmail, Amie Tan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23327

e23327 Background: Care Sequence plans, a 4R Oncology model tool (Right Information and Right Care for the Right Person at...

Long-term impacts of stomatitis and related lesions on clinical outcomes in lung cancer patients receiving chemotherapy and immunotherapy: Insights from a propensity-matched cohort study.

Lauryn Rudin, Roberto Pili, Satheesh Kumar Poolakkad Sankaran Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24205

e24205 Background: Stomatitis and related oral lesions are common adverse effects of antineoplastic therapies in lung canc...

Insurance and racial disparities in palliative care utilization and end-of-life outcomes in metastatic pancreatic cancer: A national analysis.

Lawin Steve Mathew Lasington, Jeril Lasington, Swamynathan Umamaheswaran Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16439

e16439 Background: Disparities in palliative care access and end-of-life (EOL) care intensity by insurance and race in met...

Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.

Christopher Choi, Matthew Labriola, Clara Hwang et al. Jun 01, 2026 pp. 5052-5052 10.1200/jco.2026.44.16_suppl.5052

5052 Background: Smoking has been associated with increased metastatic prostate cancer (mPC) mortality, but the mechanisms...

Evolution of treatment and survival in primary tracheal cancer: Insights from a global real-world dataset.

Nour Sabiha Naji, Deevyashali Parekh, Omar Sey et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18141

e18141 Background: Primary tracheal cancer is a rare malignancy associated with poor survival and highly heterogeneous tre...

HRD as a predictor of response to platinum-based chemotherapy and PARP inhibitors in a Chinese ovarian cancer population.

Yameng Chen, Hua Yuan, Yufei Guo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17571

e17571 Background: Homologous Recombination Deficiency (HRD) predicts response to platinum-based chemotherapy and PARP inh...

Impact of substance use disorder on pneumonia hospital outcomes in chronic lymphocytic leukemia: An inpatient nationwide analysis.

Oscar Felipe Borja Montes, Mohammed Quazi, Chiranjeevi Sainatham et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19034

e19034 Background: CLL is associated with immune dysfunction and severe infections, particularly pneumonia (PNA). Substanc...

Sequential therapy in BRAF-mutant melanoma: Comparison of combination immunotherapy anti-CTLA4 and anti–PD-1 versus anti–PD-1 monotherapy after targeted treatment failure.

Alexandr Iurchenkov, Angelina Akhmetianova, Daniil Stroyakovskiy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21527

e21527 Background: The optimal immunotherapy strategy for patients with BRAF-mutant advanced melanoma who progress on firs...

Geographic migration patterns of practicing medical oncologists in the United States, 2020-2025.

Jag S. Lally, Ryan James Crowley, David M. Kline et al. Jun 01, 2026 pp. 1527-1527 10.1200/jco.2026.44.16_suppl.1527

1527 Background: The regional provision of cancer care in the United States (US) remains plagued by disparities along the...

Prognostic effect of neoadjuvant chemotherapy in gBRCA-mutated compared to gBRCA wild-type patients with advanced HGSOC treated with first-line PARP inhibitor maintenance: A large series propensity score–matching analysis.

Ilary Ruscito, Adriana Ionelia Apostol, Giorgia Russo et al. Jun 01, 2026 pp. 5602-5602 10.1200/jco.2026.44.16_suppl.5602

5602 Background: Recent results from the TRUST trial (ENGOTov33/AGO-OVAR OP.7) have renewed interest in the prognostic rol...

Global insights into survival outcomes and unmet therapeutic needs in <i>KRAS</i> -mutant gallbladder cancer: A comprehensive federated network analysis.

Zeeshan Solangi, Ghulam Shah, Amirta Devi et al. Jun 01, 2026 pp. 4141-4141 10.1200/jco.2026.44.16_suppl.4141

4141 Background: Gallbladder cancer (GBC) is an aggressive malignancy with limited systemic options and poor survival. KRA...

De-escalation of neoadjuvant chemotherapy for HER2-positive breast cancer: A systematic review and meta-analysis.

Maria Clara Périco Perez Jun 01, 2026 pp. 616-616 10.1200/jco.2026.44.16_suppl.616

616 Background: The addition of carboplatin to taxane-based dual HER2 blockade (TCbHP) is a standard neoadjuvant regimen f...

Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST; CTRI/2017/07/009114).

Sudhir Vasudevan Nair, Tejpal Gupta, Swapnil Ulhas Rane et al. Jun 01, 2026 pp. 6000-6000 10.1200/jco.2026.44.16_suppl.6000

6000 Background: The role of adjuvant radiotherapy (RT) in early-stage, node-negative oral squamous cell carcinoma...

Regional and gender disparities in lung cancer mortality in Guatemala.

Natalia Pineda Grajeda, Alba Kihn-Alarcón Jun 01, 2026 pp. 8074-8074 10.1200/jco.2026.44.16_suppl.8074

8074 Background: Lung cancer is the leading cause of cancer-related deaths worldwide and a major contributor in Latin Amer...

Impact of preoperative breast MRI on locoregional staging and management in early breast cancer.

Ayman Rasmy, Reem Ayman, Amal Ameen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12510

e12510 Background: The role of preoperative breast MRI in early breast cancer remains controversial. We evaluated the impa...

Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno–based regimens.

David Silva Moura, Jose Lucinio Mondaza-Hernandez, Alexandra Shirikova et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23526

e23526 Background: Immunogenic cell death (ICD) is a functionally unique form of apoptosis that triggers a robust tumor-sp...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page